{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:44:12Z","timestamp":1770752652051,"version":"3.50.0"},"publisher-location":"Cham","reference-count":162,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030404635","type":"print"},{"value":"9783030404642","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/10_2019_105","type":"book-chapter","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T15:02:53Z","timestamp":1565017373000},"page":"87-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cytokines and Growth Factors"],"prefix":"10.1007","author":[{"given":"A. C.","family":"Silva","sequence":"first","affiliation":[]},{"given":"J. M. Sousa","family":"Lobo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,8,6]]},"reference":[{"key":"105_CR1","doi-asserted-by":"crossref","unstructured":"Chen Y-C, Yeh M-K (2018) Introductory chapter: biopharmaceuticals. In: Chen Y-C, Yeh M-K (eds) Biopharmaceuticals. IntechOpen, London","DOI":"10.5772\/intechopen.79194"},{"key":"105_CR2","volume-title":"Pharmaceutical biotechnology: concepts and applications","author":"G Walsh","year":"2013","unstructured":"Walsh G (2013) Pharmaceutical biotechnology: concepts and applications. Wiley, Hoboken"},{"key":"105_CR3","unstructured":"FDA (2019) What are \u201cBiologics\u201d questions and answers. https:\/\/www.fda.gov\/about-fda\/about-center-biologics-evaluation-and-research-cber\/what-are-biologics-questions-and-answers"},{"key":"105_CR4","unstructured":"EMA (2019) Biological medicine. https:\/\/www.ema.europa.eu\/en\/glossary\/biological-medicine"},{"key":"105_CR5","unstructured":"FDA (2019) Complete list of licensed products and establishments. https:\/\/www.fda.gov\/vaccines-blood-biologics\/complete-list-licensed-products-and-establishments"},{"key":"105_CR6","unstructured":"EMA (2019) Orphan designation: overview. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/orphan-designation-overview"},{"key":"105_CR7","unstructured":"EMA (2019) Biosimilar medicines: overview. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/biosimilar-medicines-overview"},{"issue":"1","key":"105_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.drudis.2018.09.011","volume":"24","author":"SB Santos","year":"2019","unstructured":"Santos SB, Lobo JMS, Silva AC (2019) Biosimilar medicines used for cancer therapy in Europe: a review. Drug Discov Today 24(1):293\u2013299","journal-title":"Drug Discov Today"},{"key":"105_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.hoc.2018.12.004","volume":"33","author":"AW Silk","year":"2019","unstructured":"Silk AW, Margolin K (2019) Cytokine therapy. Hematol Oncol Clin 33:261\u2013274","journal-title":"Hematol Oncol Clin"},{"key":"105_CR10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/B978-0-7020-6896-6.00009-0","volume-title":"Clinical immunology","author":"JJ O\u2019Shea","year":"2019","unstructured":"O\u2019Shea JJ, Gadina M, Siegel RM (2019) 9 \u2013 Cytokines and cytokine receptors. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM (eds) Clinical immunology5th edn. Elsevier, London, pp 127\u201355.e1","edition":"5"},{"issue":"2","key":"105_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/jps.24243","volume":"104","author":"T Lipi\u00e4inen","year":"2015","unstructured":"Lipi\u00e4inen T, Peltoniemi M, Sarkhel S, Yrj\u00f6nen T, Vuorela H, Urtti A et al (2015) Formulation and stability of cytokine therapeutics. J Pharm Sci 104(2):307\u2013326","journal-title":"J Pharm Sci"},{"key":"105_CR12","doi-asserted-by":"publisher","unstructured":"Hutmacher C, Neri D (2018) Antibody-cytokine fusion proteins: biopharmaceuticals with immunomodulatory properties for cancer therapy. Adv Drug Deliv Rev. https:\/\/doi.org\/10.1016\/j.addr.2018.09.002","DOI":"10.1016\/j.addr.2018.09.002"},{"key":"105_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fphar.2017.00314","volume":"8","author":"E Moorkens","year":"2017","unstructured":"Moorkens E, Meuwissen N, Huys I, Declerck P, Vulto AG, Simoens S (2017) The market of biopharmaceutical medicines: a snapshot of a diverse industrial landscape. Front Pharmacol 8:314","journal-title":"Front Pharmacol"},{"key":"105_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-6486-0","volume-title":"Pharmaceutical biotechnology fundamentals and applications","author":"DJA Crommelin","year":"2013","unstructured":"Crommelin DJA, Sindelar RD, Meibohm B (2013) Pharmaceutical biotechnology fundamentals and applications. Taylor & Francis, Milton Park"},{"key":"105_CR15","volume-title":"Pharmaceutical biotechnology: fundamentals and applications. Interferons and interleukins","author":"J-C Ryff","year":"2013","unstructured":"Ryff J-C, Bordens RW, Pestka S (2013) Interferons and interleukins. In: Crommelin DJA, Sindelar RD, Meibohm B (eds) Pharmaceutical biotechnology: fundamentals and applications. Interferons and interleukins, vol 3 edn. Informa Healthcare, New York"},{"key":"105_CR16","unstructured":"EMA (2012) EPAR summary for the public: Intron A interferon alfa 2b. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/introna-epar-summary-public_en.pdf"},{"key":"105_CR17","unstructured":"EMA (2008) European Public Assessment Assessment (EPAR): viraferon. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/viraferon-epar-summary-public_en.pdf"},{"key":"105_CR18","unstructured":"EMA (2017) EPAR summary for the public: Pegasys (peginterferon alfa-2a). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/pegasys-epar-summary-public_en.pdf"},{"key":"105_CR19","unstructured":"EMA (2006) Public statement on infergen: interferon alfacon-1. https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/public-statement-infergen-interferon-alfacon-1-withdrawal-marketing-authorisation-european-union_en.pdf"},{"key":"105_CR20","unstructured":"FDA (2008) ROFERON\u00ae-A: Interferon alfa-2a, recombinant"},{"key":"105_CR21","unstructured":"EMA (2012) EPAR summary for the public: PegIntron (peginterferon alfa-2b). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/pegintron-epar-summary-public_en.pdf"},{"key":"105_CR22","unstructured":"Corporation MSD (2015). Sylatron\u2122 (peginterferon alfa-2b). https:\/\/www.merck.com\/product\/usa\/pi_circulars\/s\/sylatron\/sylatron_pi.pdf"},{"key":"105_CR23","volume-title":"Alferon N injection\u00ae (Interferon alfa-n3)","author":"H Biopharma","year":"2019","unstructured":"Biopharma H (2019) Alferon N injection\u00ae (Interferon alfa-n3). https:\/\/hemispherx.net\/products\/"},{"key":"105_CR24","unstructured":"EMA (2012) EPAR summary for the public: Betaferon (interferon beta-1b). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/betaferon-epar-summary-public_en.pdf"},{"key":"105_CR25","unstructured":"EMA (2011) EPAR summary for the public: Avonex (interferon beta-1a). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/avonex-epar-summary-public_en.pdf"},{"key":"105_CR26","unstructured":"EMA (2014) EPAR summary for the public: rebif (interferon beta-1a). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/rebif-epar-summary-public_en.pdf"},{"key":"105_CR27","unstructured":"EMA (2014) EPAR summary for the public: Plegridy (peginterferon beta-1a). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/plegridy-epar-summary-public_en.pdf"},{"key":"105_CR28","unstructured":"EMA (2012) EPAR summary for the public: Extavia (interferon beta-1b). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/extavia-epar-summary-public_en.pdf"},{"key":"105_CR29","unstructured":"Horizon Pharma (2018) Actimmune\u00ae (Interferon gamma-1b). https:\/\/www.actimmune.com\/"},{"key":"105_CR30","volume-title":"E. clinical commissioning policy: anakinra to treat periodic fevers and autoinflammatory diseases (all ages)","author":"National Health Service (NHS)","year":"2018","unstructured":"National Health Service (NHS) (2018) E. clinical commissioning policy: anakinra to treat periodic fevers and autoinflammatory diseases (all ages)"},{"key":"105_CR31","volume-title":"E. clinical commissioning policy: anakinra\/tocilizumab for the treatment of adult-onset Still\u2019s disease refractory to second-line therapy (adults)","author":"National Health Service (NHS)","year":"2018","unstructured":"National Health Service (NHS) (2018) E. clinical commissioning policy: anakinra\/tocilizumab for the treatment of adult-onset Still\u2019s disease refractory to second-line therapy (adults)"},{"key":"105_CR32","unstructured":"EMA (2009) Kineret (anakinra): an overview of Kineret and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/kineret-epar-medicine-overview_en.pdf"},{"key":"105_CR33","unstructured":"EMA (2008) Public summary of positive opinion for orphan designation of human interleukin-2 (glycosylated tetrasaccharide, glycosylated trisaccharide and nonglycosylated) (inhalation use) for the treatment of renal cell carcinoma. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/06\/417-public-summary-positive-opinion-orphan-designation-human-interleukin-2-glycosylated_en.pdf"},{"key":"105_CR34","unstructured":"FDA (2014) Current and resolved drug shortages and discontinuations reported to FDA. https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/dsp_ActiveIngredientDetails.cfm?AI=Denileukin+Diftitox+%28Ontak%29+Injection&st=d&tab=tabs-2"},{"key":"105_CR35","unstructured":"EMA (2015) Public summary of opinion on orphan designation: recombinant human interleukin-3 truncated diphtheria toxin fusion protein for the treatment of acute myeloid leukaemia"},{"key":"105_CR36","volume-title":"Public summary of opinion on orphan designation: recombinant human interleukin-7 for the treatment of progressive multifocal leukoencephalopathy","author":"EM Agency","year":"2014","unstructured":"Agency EM (2014) Public summary of opinion on orphan designation: recombinant human interleukin-7 for the treatment of progressive multifocal leukoencephalopathy. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/12\/1013-public-summary-opinion-orphan-designation-recombinant-human-interleukin-7-treatment-progressive_en.pdf"},{"key":"105_CR37","unstructured":"EMA (2017) Public summary of opinion on orphan designation: recombinant human interleukin-7 fused to a hybrid crystallisable fragment region of a human antibody for treatment of idiopathic CD4 lymphocytopenia. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/17\/1875-public-summary-opinion-orphan-designation-recombinant-human-interleukin-7-fused-hybrid_en.pdf"},{"key":"105_CR38","unstructured":"EMA (2017) Public summary of opinion on orphan designation: pegylated recombinant human interleukin-10 for the treatment of pancreatic cancer. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/16\/1804-public-summary-opinion-orphan-designation-pegylated-recombinant-human-interleukin-10-treatment_en.pdf"},{"key":"105_CR39","unstructured":"EMA (2016) Public summary of opinion on orphan designation: recombinant human interleukin-12 for treatment of acute radiation syndrome. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/16\/1727-public-summary-opinion-orphan-designation-recombinant-human-interleukin-12-treatment-acute_en.pdf"},{"key":"105_CR40","unstructured":"EMA (2017) European public assessment report (EPAR): Beromun. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/beromun-epar-summary-public_en.pdf"},{"key":"105_CR41","unstructured":"EMA (2017). Withdrawal of the marketing authorisation application for Zafiride (NGR-human tumour necrosis factor alpha). https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis_en.pdf"},{"key":"105_CR42","unstructured":"EMA (2008) Public summary of positive opinion for orphan designation of NGR-human tumour necrosis factor for the treatment of malignant mesothelioma. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/08\/549-public-summary-positive-opinion-orphan-designation-ngr-human-tumour-necrosis-factor-treatment_en.pdf"},{"key":"105_CR43","unstructured":"EMA (2009) Public summary of positive opinion for orphan designation of NGR-human tumour necrosis factor for the treatment of hepatocellular carcinoma. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/09\/686-public-summary-positive-opinion-orphan-designation-ngr-human-tumour-necrosis-factor-treatment_en.pdf"},{"issue":"4","key":"105_CR44","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1517\/14712598.2016.1135898","volume":"16","author":"K Brar","year":"2016","unstructured":"Brar K, Leung DYM (2016) Recent considerations in the use of recombinant interferon gamma for biological therapy of atopic dermatitis. Expert Opin Biol Ther 16(4):507\u2013514","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"105_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1208\/s12248-019-0300-7","volume":"21","author":"EF Mufarrege","year":"2019","unstructured":"Mufarrege EF, Haile LA, Etcheverrigaray M, Verthelyi DI (2019) Multiplexed gene expression as a characterization of bioactivity for interferon beta (IFN-\u03b2) biosimilar candidates: impact of innate immune response modulating impurities (IIRMIs). AAPS J 21(2):26","journal-title":"AAPS J"},{"issue":"7","key":"105_CR46","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1046\/j.1365-2230.2002.01144.x","volume":"27","author":"K Asadullah","year":"2002","unstructured":"Asadullah K, Sterry W, Trefzer U (2002) Cytokines: interleukin and interferon therapy in dermatology. Clin Exp Dermatol 27(7):578\u2013584","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"105_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.13224","volume":"195","author":"C Steen-Louws","year":"2019","unstructured":"Steen-Louws C, Hartgring SAY, Popov-Celeketic J, Lopes AP, de Smet MBM, Eijkelkamp N et al (2019) IL4-10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10. Clin Exp Immunol 195(1):1\u20139","journal-title":"Clin Exp Immunol"},{"key":"105_CR48","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41423-018-0055-6","volume":"16","author":"B Gao","year":"2018","unstructured":"Gao B, Xiang X (2018) Interleukin-22 from bench to bedside: a promising drug for epithelial repair. Cell Mol Immunol 16:666\u2013667","journal-title":"Cell Mol Immunol"},{"key":"105_CR49","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41423-018-0029-8","volume":"16","author":"K-Y Tang","year":"2019","unstructured":"Tang K-Y, Lickliter J, Huang Z-H, Xian Z-S, Chen H-Y, Huang C et al (2019) Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects. Cell Mol Immunol 16:473\u2013482","journal-title":"Cell Mol Immunol"},{"issue":"29","key":"105_CR50","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.2016.69.6435","volume":"34","author":"H Zhang","year":"2016","unstructured":"Zhang H, Wang Y, Hwang ES, He Y-W (2016) Interleukin-10: an immune-activating cytokine in cancer immunotherapy. J Clin Oncol 34(29):3576\u20133578","journal-title":"J Clin Oncol"},{"issue":"29","key":"105_CR51","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","volume":"34","author":"A Naing","year":"2016","unstructured":"Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ et al (2016) Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol 34(29):3562\u20133569","journal-title":"J Clin Oncol"},{"key":"105_CR52","unstructured":"Pembrolizumab and Recombinant Interleukin-12 in Treating Patients with Solid Tumors [Internet] (2019). https:\/\/www.cancer.gov\/about-cancer\/treatment\/clinical-trials\/search\/v?id=NCI-2017-00091&r=1"},{"issue":"15_suppl","key":"105_CR53","doi-asserted-by":"publisher","first-page":"TPS3128","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3128","volume":"36","author":"GHOS Coyne","year":"2018","unstructured":"Coyne GHOS, Conlon K, Takebe N, Streicher H, Quinn MF, Bruns A et al (2018) Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers. J Clin Oncol 36(15_suppl):TPS3128\u2013TPS3TPS","journal-title":"J Clin Oncol"},{"issue":"7","key":"105_CR54","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-17-2451","volume":"24","author":"JS Miller","year":"2018","unstructured":"Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA et al (2018) A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors. Clin Cancer Res 24(7):1525\u20131535","journal-title":"Clin Cancer Res"},{"issue":"5","key":"105_CR55","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98960","volume":"3","author":"B Francois","year":"2018","unstructured":"Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J et al (2018) Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight 3(5):e98960","journal-title":"JCI Insight"},{"issue":"2","key":"105_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023765","volume":"9","author":"MG Thomas","year":"2019","unstructured":"Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V et al (2019) Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of interleukin 1 blockade in acute severe colitis: the IASO trial. BMJ Open 9(2):e023765","journal-title":"BMJ Open"},{"key":"105_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopha.2018.12.031","volume":"111","author":"J Zhu","year":"2019","unstructured":"Zhu J, Huang J, Dai D, Wang X, Gao J, Han W et al (2019) Recombinant human interleukin-1 receptor antagonist treatment protects rats from myocardial ischemia\u2013reperfusion injury. Biomed Pharmacother 111:1\u20135","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"105_CR58","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/BOR.0000000000000575","volume":"31","author":"JY Humrich","year":"2019","unstructured":"Humrich JY, Riemekasten G (2019) Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 31(2):208\u2013212","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"105_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201025","volume":"13","author":"R Zhang","year":"2018","unstructured":"Zhang R, Xi X, Wang C, Pan Y, Ge C, Zhang L et al (2018) Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: a systematic review and meta-analysis. PLoS One 13(7):e0201025","journal-title":"PLoS One"},{"key":"105_CR60","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.taap.2018.01.016","volume":"342","author":"K-M Yu","year":"2018","unstructured":"Yu K-M, Lau JY-N, Fok M, Yeung Y-K, Fok S-P, Zhang S et al (2018) Preclinical evaluation of the mono-PEGylated recombinant human interleukin-11 in cynomolgus monkeys. Toxicol Appl Pharmacol 342:39\u201349","journal-title":"Toxicol Appl Pharmacol"},{"key":"105_CR61","unstructured":"NCI (2019) NCI dictionary of cancer terms: tumor necrosis factor. https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/tumor-necrosis-factor"},{"issue":"1","key":"105_CR62","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/1759-7714.12296","volume":"7","author":"Q Li","year":"2016","unstructured":"Li Q, Sun W, Yuan D, Lv T, Yin J, Cao E et al (2016) Efficacy and safety of recombinant human tumor necrosis factor application for the treatment of malignant pleural effusion caused by lung cancer. Thorac Cancer 7(1):136\u2013139","journal-title":"Thorac Cancer"},{"key":"105_CR63","volume-title":"Pharmaceutical biotechnology: fundamentals and applications","author":"M Foote","year":"2013","unstructured":"Foote M (2013) Hematopoietic growth factors. In: Crommelin DJA, Sindelar RD, Meibohm B (eds) Pharmaceutical biotechnology: fundamentals and applications3rd edn. Informa Healthcare, London","edition":"3"},{"issue":"21","key":"105_CR64","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1056\/NEJM198911233212106","volume":"321","author":"JE Groopman","year":"1989","unstructured":"Groopman JE, Molina J-M, Scadden DT (1989) Hematopoietic growth factors. N Engl J Med 321(21):1449\u20131459","journal-title":"N Engl J Med"},{"issue":"19","key":"105_CR65","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1056\/NEJMra052706","volume":"354","author":"K Kaushansky","year":"2006","unstructured":"Kaushansky K (2006) Lineage-specific hematopoietic growth factors. N Engl J Med 354(19):2034\u20132045","journal-title":"N Engl J Med"},{"key":"105_CR66","unstructured":"EMA (2018) Epoetin Alfa Hexal (epoetin alfa): an overview of Epoetin Alfa Hexal and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/epoetin-alfa-hexal-epar-summary-public_en-0.pdf"},{"key":"105_CR67","unstructured":"EMA (2018) Abseamed (epoetin alfa): an overview of Abseamed and why it is authorised in the EU"},{"key":"105_CR68","unstructured":"EMA (2018) Binocrit (epoetin alfa): an overview of Binocrit and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/binocrit-epar-medicine-overview_en.pdf"},{"key":"105_CR69","unstructured":"FDA (2017) Information for epogen\/procrit (epoetin alfa). https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm541173.htm"},{"key":"105_CR70","unstructured":"EMA (2015) EPAR summary for the public: NeoRecormon \u2013 epoetin beta. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/neorecormon-epar-summary-public_en.pdf"},{"key":"105_CR71","unstructured":"EMA (2012) EPAR summary for the public: mircera \u2013 methoxy polyethylene glycol-epoetin beta. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mircera-epar-summary-public_en.pdf"},{"key":"105_CR72","unstructured":"FDA (2018) FDA approves Mircera for anemia associated with chronic kidney disease in pediatric patients on dialysis. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm610210.htm"},{"key":"105_CR73","unstructured":"EMA (2009) EPAR summary for the public: eporatio \u2013 epoetin theta. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/eporatio-epar-summary-public_en.pdf"},{"key":"105_CR74","unstructured":"EMA (2009) EPAR summary for the public: biopoin \u2013 epoetin theta. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/biopoin-epar-summary-public_en.pdf"},{"key":"105_CR75","unstructured":"EMA (2019) Silapo (epoetin zeta): an overview of Silapo and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/silapo-epar-medicine-overview_en.pdf"},{"key":"105_CR76","unstructured":"EMA (2011) EPAR summary for the public: retacrit \u2013 epoetin zeta. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/retacrit-epar-summary-public_en.pdf"},{"key":"105_CR77","unstructured":"FDA (2018) FDA approves first epoetin alfa biosimilar for the treatment of anemia. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm607703.htm"},{"key":"105_CR78","unstructured":"EMA (2013) EPAR summary for the public: Aranesp \u2013 darbepoetin alfa. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/aranesp-epar-summary-public_en.pdf"},{"key":"105_CR79","unstructured":"EMA (2009) EPAR summary for the public: NESPO \u2013 darbepoetin alfa. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/nespo-epar-summary-public_en.pdf"},{"key":"105_CR80","unstructured":"FDA (2017) Information for Aranesp (darbepoetin alfa). https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm541148.htm"},{"key":"105_CR81","unstructured":"EMA (2017) EPAR summary for the public: Biograstim. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/biograstim-epar-summary-public_en.pdf"},{"key":"105_CR82","unstructured":"EMA (2008) EPAR summary for the public: Tevagrastim. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/tevagrastim-epar-summary-public_en.pdf"},{"key":"105_CR83","unstructured":"EMA (2014) EPAR summary for the public: Zarzio. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/zarzio-epar-summary-public_en.pdf"},{"key":"105_CR84","unstructured":"EMA (2014) EPAR summary for the public: Ratiograstim. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/ratiograstim-epar-summary-public_en.pdf"},{"key":"105_CR85","unstructured":"EMA (2018) EPAR summary for the public: Grastofil. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/grastofil-epar-medicine-overview_en.pdf"},{"key":"105_CR86","unstructured":"EMA (2010) EPAR summary for the public: Nivestim. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/nivestim-epar-summary-public_en.pdf"},{"key":"105_CR87","unstructured":"EMA (2014) EPAR summary for the public: Accofil. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/accofil-epar-summary-public_en.pdf"},{"key":"105_CR88","unstructured":"EMA (2014) EPAR summary for the public: Filgrastim Hexal. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/filgrastim-hexal-epar-summary-public_en.pdf"},{"key":"105_CR89","unstructured":"EMA (2011) EPAR summary for the public: Filgrastim Ratiopharm. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/filgrastim-ratiopharm-epar-summary-public_en.pdf"},{"key":"105_CR90","unstructured":"FDA (2015) FDA approves Neupogen for treatment of patients with radiation-induced myelosuppression following a radiological\/nuclear incident. https:\/\/www.fda.gov\/EmergencyPreparedness\/Counterterrorism\/MedicalCountermeasures\/AboutMCMi\/ucm443245.htm"},{"key":"105_CR91","unstructured":"FDA (2015) Prescribing information for Zarxio. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125553lbl.pdf"},{"key":"105_CR92","unstructured":"FDA (2018) Prescribing information for Nivestym. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761080s000lbl.pdf"},{"key":"105_CR93","unstructured":"EMA (2015) Public summary of opinion on orphan designation: filgrastim for the treatment of amyotrophic lateral sclerosis. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/08\/532-public-summary-positive-opinion-orphan-designation-filgrastim-treatment-amyotrophic-lateral_en.pdf"},{"key":"105_CR94","unstructured":"EMA (2015) Public summary of opinion on orphan designation: Filgrastim for the treatment of spinal cord injury. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/08\/580-public-summary-positive-opinion-orphan-designation-filgrastim-treatment-spinal-cord-injury_en.pdf"},{"key":"105_CR95","unstructured":"EMA (2018) EPAR summary for the public: Fulphila (pegfilgrastim). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/fulphila-epar-medicine-overview_en.pdf"},{"key":"105_CR96","unstructured":"FDA (2018) Prescribing information for Fulphila. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761075s000lbl.pdf"},{"key":"105_CR97","unstructured":"EMA. EPAR summary for the public: Udenyca (pegfilgrastim). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/udenyca-epar-medicine-overview_en.pdf"},{"key":"105_CR98","unstructured":"FDA (2018) Prescribing information for UDENYCA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761039s000lbl.pdf"},{"key":"105_CR99","unstructured":"EMA (2018) EPAR summary for the public: Ziextenzo (pegfilgrastim). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/ziextenzo-epar-medicine-overview_en.pdf"},{"key":"105_CR100","unstructured":"EMA (2018) EPAR summary for the public: Pelgraz (pegfilgrastim). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/pelgraz-epar-medicine-overview_en.pdf"},{"key":"105_CR101","unstructured":"EMA (2018) EPAR summary for the public: Pelmeg (pegfilgrastim). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/pelmeg-epar-medicine-overview_en.pdf"},{"key":"105_CR102","unstructured":"EMA (2015) EPAR summary for the public: Ristempa (pegfilgrastim). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/ristempa-epar-summary-public_en.pdf"},{"key":"105_CR103","unstructured":"EMA (2009) EPAR summary for the public: Neupopeg (pegfilgrastim). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/neupopeg-epar-summary-public_en.pdf"},{"key":"105_CR104","unstructured":"EMA (2018) Withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim). https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_en-0.pdf"},{"key":"105_CR105","unstructured":"EMA (2018) Withdrawal of the marketing authorisation application for Cavoley (pegfilgrastim). https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_en-0.pdf"},{"key":"105_CR106","unstructured":"EMA (2018) EPAR summary for the public: Neulasta (pegfilgrastim). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/neulasta-epar-medicine-overview_en.pdf"},{"key":"105_CR107","unstructured":"EMA (2013) EPAR summary for the public: Lonquex (lipegfilgrastim). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/lonquex-epar-summary-public_en.pdf"},{"key":"105_CR108","unstructured":"FDA (2012) Prescribing information for Granix. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125294s0000lbl.pdf"},{"key":"105_CR109","unstructured":"EMA (2016) Public summary of opinion on orphan designation: Molgramostim for the treatment of acute respiratory distress syndrome. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/16\/1685-public-summary-opinion-orphan-designation-molgramostim-treatment-acute-respiratory-distress_en.pdf"},{"key":"105_CR110","unstructured":"FDA (2018) https:\/\/www.fda.gov\/EmergencyPreparedness\/Counterterrorism\/MedicalCountermeasures\/MCMIssues\/ucm602102.htm . https:\/\/www.fda.gov\/EmergencyPreparedness\/Counterterrorism\/MedicalCountermeasures\/MCMIssues\/ucm602102.htm"},{"key":"105_CR111","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.drudis.2019.03.016","volume":"24","author":"SW Burchiel","year":"2019","unstructured":"Burchiel SW, Aspbury R, Munday J (2019) The search for biosimilars and biobetters. Drug Discov Today 24:1087\u20131091","journal-title":"Drug Discov Today"},{"key":"105_CR112","volume-title":"Biosimilar approvals in Europe","author":"JF Siegel","year":"2017","unstructured":"Siegel JF, Royzman I (2017) Biosimilar approvals in Europe. https:\/\/www.biologicsblog.com\/2017-biosimilar-approvals-in-europe"},{"key":"105_CR113","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.critrevonc.2019.01.021","volume":"136","author":"L Affentranger","year":"2019","unstructured":"Affentranger L, Bohlius J, Hallal M, Bonadies N (2019) Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: a systematic review. Crit Rev Oncol Hematol 136:37\u201347","journal-title":"Crit Rev Oncol Hematol"},{"key":"105_CR114","doi-asserted-by":"publisher","first-page":"e13541","DOI":"10.1111\/ctr.13541","volume":"33","author":"S Hamel","year":"2019","unstructured":"Hamel S, Kuo V, Sawinski D, Johnson D, Bloom RD, Bleicher M et al (2019) Single center, real-world experience with granulocyte colony-stimulating factor for management of leukopenia following kidney transplantation. Clin Transpl 33:e13541","journal-title":"Clin Transpl"},{"key":"105_CR115","doi-asserted-by":"publisher","unstructured":"Kamath MS, Kirubakaran R, Sunkara SK (2018) Granulocyte-colony stimulating factor administration for subfertile women undergoing assisted reproduction. Cochrane Database Syst Rev 12. https:\/\/doi.org\/10.1002\/14651858.CD013226","DOI":"10.1002\/14651858.CD013226"},{"issue":"5","key":"105_CR116","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00404-018-4892-4","volume":"298","author":"L Zhang","year":"2018","unstructured":"Zhang L, Xu W-H, Fu X-H, Huang Q-X, Guo X-Y, Zhang L et al (2018) Therapeutic role of granulocyte colony-stimulating factor (G-CSF) for infertile women under in vitro fertilization and embryo transfer (IVF-ET) treatment: a meta-analysis. Arch Gynecol Obstet 298(5):861\u2013871","journal-title":"Arch Gynecol Obstet"},{"key":"105_CR117","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fbioe.2018.00005","volume":"6","author":"M Herrmann","year":"2018","unstructured":"Herrmann M, Zeiter S, Eberli U, Hildebrand M, Camenisch K, Menzel U et al (2018) Five days granulocyte colony-stimulating factor treatment increases bone formation and reduces gap size of a rat segmental bone defect: a pilot study. Front Bioeng Biotechnol 6:5","journal-title":"Front Bioeng Biotechnol"},{"key":"105_CR118","volume-title":"Patient product information: REGEN-D\u00ae 150","author":"B Biotech","year":"2019","unstructured":"Biotech B (2019) Patient product information: REGEN-D\u00ae 150. https:\/\/www.bharatbiotech.com\/images\/regend150\/REGEN-D150_ppi.pdf"},{"key":"105_CR119","volume-title":"Patient product information: REGEN-D\u00ae 60","author":"B Biotech","year":"2019","unstructured":"Biotech B (2019) Patient product information: REGEN-D\u00ae 60. https:\/\/www.bharatbiotech.com\/images\/regend60\/regen-d%2060-ppi.pdf"},{"issue":"1","key":"105_CR120","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1590\/S1555-79602013000100004","volume":"15","author":"J Berlanga","year":"2013","unstructured":"Berlanga J, F\u00e9rnandez J, L\u00f3pez E, L\u00f3pez P, del R\u00edo A, Valenzuela C et al (2013) Heberprot-P: a novel product for treating advanced diabetic foot ulcer. MEDICC Rev 15(1):11\u201315","journal-title":"MEDICC Rev"},{"issue":"1","key":"105_CR121","first-page":"10","volume":"7","author":"S Yamakawa","year":"2019","unstructured":"Yamakawa S, Hayashida K (2019) Advances in surgical applications of growth factors for wound healing. Burns Trauma 7(1):10","journal-title":"Burns Trauma"},{"key":"105_CR122","unstructured":"EMA (2017) EMA decision of 30 January 2018 on the granting of a product specific waiver for recombinant human epidermal growth factor. https:\/\/www.ema.europa.eu\/en\/documents\/pip-decision\/p\/0038\/2018-ema-decision-30-january-2018-granting-product-specific-waiver-recombinant-human-epidermal_en.pdf"},{"issue":"1","key":"105_CR123","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/09546634.2018.1468546","volume":"30","author":"J Esquirol-Caussa","year":"2019","unstructured":"Esquirol-Caussa J, Herrero-Vila E (2019) Human recombinant epidermal growth factor in skin lesions: 77 cases in EPItelizando project. J Dermatol Treat 30(1):96\u2013101","journal-title":"J Dermatol Treat"},{"issue":"5","key":"105_CR124","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/17460441.2019.1588879","volume":"14","author":"E \u00d6hnstedt","year":"2019","unstructured":"\u00d6hnstedt E, Lofton Tomenius H, V\u00e5gesj\u00f6 E, Phillipson M (2019) The discovery and development of topical medicines for wound healing. Expert Opin Drug Discovery 14(5):485\u2013497","journal-title":"Expert Opin Drug Discovery"},{"key":"105_CR125","unstructured":"EMA (2012) EPAR summary for the public: Regranex (becaplermin). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/regranex-epar-summary-public_en.pdf"},{"key":"105_CR126","unstructured":"EMA (2012) Public statement on Regranex (becaplermin): withdrawal of the marketing authorisation in the European Union. https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/public-statement-regranex-withdrawal-marketing-authorisation-european-union_en.pdf"},{"key":"105_CR127","unstructured":"FDA (2018) Summary of safety and effectiveness data: Augment\u00ae Injectable. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf10\/P100006S005b.pdf"},{"issue":"1","key":"105_CR128","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.fas.2016.02.001","volume":"23","author":"H Sun","year":"2017","unstructured":"Sun H, Lu P-P, Zhou P-H, Sun S-W, Zhang H-T, Liu Y-J et al (2017) Recombinant human platelet-derived growth factor-BB versus autologous bone graft in foot and ankle fusion: a systematic review and meta-analysis. Foot Ankle Surg 23(1):32\u201339","journal-title":"Foot Ankle Surg"},{"key":"105_CR129","volume-title":"GEM 21S\u00ae","author":"L Biologics","year":"2019","unstructured":"Biologics L (2019) GEM 21S\u00ae. https:\/\/lynchbiologics.com\/products\/gem-21s\/"},{"key":"105_CR130","unstructured":"KAKEN Pharmaceutical CO (2019) L. Fiblast\u00ae (Recombinant human basic fibroblast growth factor, rh bFGF). http:\/\/www.kaken.co.jp\/english\/business\/rd_pipeline.html"},{"key":"105_CR131","unstructured":"EMA (2014) Public summary of opinion on orphan designation: variant of recombinant human fibroblast growth factor 19 for the treatment of primary biliary cirrhosis. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/14\/1329-public-summary-opinion-orphan-designation-variant-recombinant-human-fibroblast-growth-factor-19_en.pdf"},{"key":"105_CR132","unstructured":"Agency EM (2016) Public summary of opinion on orphan designation: Variant of recombinant human fibroblast growth factor 19 for the treatment of primary sclerosing cholangitis. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/15\/1584-public-summary-opinion-orphan-designation-variant-recombinant-human-fibroblast-growth-factor-19_en.pdf"},{"key":"105_CR133","unstructured":"EMA (2016) EPAR summary for the public: Kepivance (palifermin). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/kepivance-epar-summary-public_en.pdf"},{"issue":"1","key":"105_CR134","doi-asserted-by":"publisher","first-page":"30","DOI":"10.12968\/jowc.2008.17.1.27917","volume":"17","author":"JR Hanft","year":"2008","unstructured":"Hanft JR, Pollak RA, Barbul A, van Gils C, Kwon PS, Gray SM et al (2008) Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J Wound Care 17(1):30\u201337","journal-title":"J Wound Care"},{"key":"105_CR135","unstructured":"EMA (2010) Public summary of opinion on orphan designation: Recombinant human vascular endothelial growth factor for the treatment of amyotrophic lateral sclerosis. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/09\/711-public-summary-opinion-orphan-designation-recombinant-human-vascular-endothelial-growth-factor_en.pdf"},{"issue":"4","key":"105_CR136","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00210-019-01629-y","volume":"392","author":"AWK Yeung","year":"2019","unstructured":"Yeung AWK, Abdel-Daim MM, Abushouk AI, Kadonosono K (2019) A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach. Naunyn Schmiedeberg\u2019s Arch Pharmacol 392(4):393\u2013403","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"105_CR137","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.preghy.2018.03.003","volume":"14","author":"D Hayes Ryan","year":"2018","unstructured":"Hayes Ryan D, McCarthy FP, O'Donoghue K, Kenny LC (2018) Placental growth factor: a review of literature and future applications. Pregnancy Hypertens 14:260\u2013264","journal-title":"Pregnancy Hypertens"},{"issue":"1, Suppl","key":"105_CR138","doi-asserted-by":"publisher","first-page":"S298","DOI":"10.1016\/j.ajog.2018.11.463","volume":"220","author":"JG Parchem","year":"2019","unstructured":"Parchem JG, Brock C, Sibai BM (2019) 442: plasma placental growth factor and the risk of adverse perinatal outcome. Am J Obstet Gynecol 220(1, Suppl):S298","journal-title":"Am J Obstet Gynecol"},{"key":"105_CR139","unstructured":"EMA (2018) Public summary of opinion on orphan designation: recombinant human placental growth factor for the treatment of pre-eclampsia. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/18\/2040-public-summary-opinion-orphan-designation-recombinant-human-placental-growth-factor-treatment_en.pdf"},{"issue":"1","key":"105_CR140","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13287-019-1203-3","volume":"10","author":"A Shpichka","year":"2019","unstructured":"Shpichka A, Butnaru D, Bezrukov EA, Sukhanov RB, Atala A, Burdukovskii V et al (2019) Skin tissue regeneration for burn injury. Stem Cell Res Ther 10(1):94","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"105_CR141","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/PRS.0b013e318217429b","volume":"128","author":"K So","year":"2011","unstructured":"So K, McGrouther DA, Bush JA, Durani P, Taylor L, Skotny G et al (2011) Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial. Plast Reconstr Surg 128(1):163\u2013172","journal-title":"Plast Reconstr Surg"},{"key":"105_CR142","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrc2536","volume":"8","author":"M Pollak","year":"2008","unstructured":"Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"105_CR143","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S1470-2045(10)70095-4","volume":"11","author":"T Key","year":"2010","unstructured":"Key T, Appleby P, Reeves G, Roddam A, Endogenous Hormones and Breast Cancer Collaborative Group (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11(6):530\u2013542","journal-title":"Lancet Oncol"},{"issue":"8","key":"105_CR144","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1158\/0008-5472.CAN-15-1551","volume":"76","author":"RC Travis","year":"2016","unstructured":"Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A et al (2016) A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res 76(8):2288\u20132300","journal-title":"Cancer Res"},{"issue":"6","key":"105_CR145","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/1055-9965.EPI-13-1210-T","volume":"23","author":"JA Schmidt","year":"2014","unstructured":"Schmidt JA, Allen NE, Almquist M, Franceschi S, Rinaldi S, Tipper SJ et al (2014) Insulin-like growth factor-i and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Prev Biomark 23(6):976\u2013985","journal-title":"Cancer Epidemiol Prev Biomark"},{"key":"105_CR146","unstructured":"Biopharmaceuticals I (2019) INCRELEX\u00ae: full prescribing information. https:\/\/www.ipsen.com\/websites\/Ipsen_Online\/wp-content\/uploads\/sites\/9\/2019\/01\/21153952\/Increlex_Full_Prescribing_Information1.pdf"},{"key":"105_CR147","unstructured":"FDA (2009) Access to Iplex for patients with ALS. https:\/\/www.fda.gov\/Drugs\/ResourcesForYou\/HealthProfessionals\/ucm118117.htm"},{"key":"105_CR148","unstructured":"EMA (2004) Public summary of opinion on orphan designation: recombinant human insulin-like growth factor-I\/recombinant human insulin-like growth factor binding protein-3 for the treatment of Type A extreme insulin resistance syndrome. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/04\/236-public-summary-opinion-orphan-designation-recombinant-human-insulin-growth-factor-i\/recombinant-human-insulin-growth-factor-binding-protein-3-treatment-type-extreme-insulin-resi_en.pdf"},{"key":"105_CR149","unstructured":"EMA (2011) Public summary of opinion on orphan designation: recombinant human insulin-like growth factor-I\/recombinant human insulin like growth factor binding protein-3 for the treatment of Type B extreme insulin resistance syndrome. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/04\/235-public-summary-positive-opinion-orphan-designation-recombinant-human-insulin-growth-factor-i\/recombinant-human-insulin-growth-factor-binding-protein-3-treatment-type-b-extreme-insu_en.pdf"},{"key":"105_CR150","unstructured":"EMA (2004) Public summary of opinion on orphan designation: recombinant human insulin-like growth factor-I\/recombinant human insulin like growth factor binding protein-3 for the treatment of Rabson Mendenhall syndrome. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/04\/237-public-summary-positive-opinion-orphan-designation-recombinant-human-insulin-growth-factor-i\/recombinant-human-insulin-growth-factor-binding-protein-3-treatment-rabson-mendnhal_en.pdf"},{"key":"105_CR151","unstructured":"EMA (2011) Public summary of opinion on orphan designation: recombinant human insulin-like growth factor-I\/recombinant human insulin-like growth factor binding protein-3 for the treatment of primary growth hormone insensitivity syndrome (Laron Syndrome). https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/03\/159-public-summary-positive-opinion-orphan-designation-recombinant-human-insulin-growth-factor-i\/recombinant-human-insulin-growth-factor-binding-protein-3-treatment-primary-growt_en.pdf"},{"key":"105_CR152","unstructured":"EMA (2011) Public summary of opinion on orphan designation: recombinant human insulin-like growth factor-I\/recombinant human insulin like growth factor binding protein-3 for the treatment of leprechaunism. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/04\/238-public-summary-positive-opinion-orphan-designation-recombinant-human-insulin-growth-factor-i\/recombinant-human-insulin-growth-factor-binding-protein-3-treatment-leprechaunism_en.pdf"},{"issue":"1","key":"105_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/imm.12717","volume":"151","author":"SD Skaper","year":"2017","unstructured":"Skaper SD (2017) Nerve growth factor: a neuroimmune crosstalk mediator for all seasons. Immunology 151(1):1\u201315","journal-title":"Immunology"},{"key":"105_CR154","unstructured":"EMA (2015) Public summary of opinion on orphan designation: recombinant human nerve growth factor for the treatment of retinitis pigmentosa. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/13\/1135-public-summary-opinion-orphan-designation-recombinant-human-nerve-growth-factor-treatment_en.pdf"},{"key":"105_CR155","unstructured":"EMA (2015) Public summary of opinion on orphan designation: recombinant human nerve growth factor for the treatment of neurotrophic keratitis. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/15\/1586-public-summary-opinion-orphan-designation-recombinant-human-nerve-growth-factor-treatment_en.pdf"},{"key":"105_CR156","unstructured":"FDA (2018) Prescribing information for OXERVATE. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761094s000lbl.pdf"},{"issue":"2","key":"105_CR157","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1007\/s12035-018-1154-1","volume":"56","author":"LA Mesentier-Louro","year":"2019","unstructured":"Mesentier-Louro LA, Rosso P, Carito V, Mendez-Otero R, Santiago MF, Rama P et al (2019) Nerve growth factor role on retinal ganglion cell survival and axon regrowth: effects of ocular administration in experimental model of optic nerve injury. Mol Neurobiol 56(2):1056\u20131069","journal-title":"Mol Neurobiol"},{"key":"105_CR158","doi-asserted-by":"publisher","unstructured":"Sacchetti M, Lambiase A, Schmidl D, Schmetterer L, Ferrari M, Mantelli F et al (2019) Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312470","DOI":"10.1136\/bjophthalmol-2018-312470"},{"issue":"1","key":"105_CR159","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13046-016-0395-y","volume":"35","author":"L Aloe","year":"2016","unstructured":"Aloe L, Rocco ML, Balzamino BO, Micera A (2016) Nerve growth factor: role in growth, differentiation and controlling cancer cell development. J Exp Clin Cancer Res 35(1):116","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"105_CR160","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-neuro-072116-031121","volume":"40","author":"F Denk","year":"2017","unstructured":"Denk F, Bennett DL, McMahon SB (2017) Nerve growth factor and pain mechanisms. Annu Rev Neurosci 40(1):307\u2013325","journal-title":"Annu Rev Neurosci"},{"key":"105_CR161","unstructured":"Biopharmaceuticals I (2019) Increlex\u00ae (mecasermin). https:\/\/www.increlex.com\/"},{"key":"105_CR162","unstructured":"Insmed (2009) Insmed provides update on supply of IPLEX\u00ae. https:\/\/web.archive.org\/web\/20170902142334\/http:\/\/investor.insmed.com\/releasedetail.cfm?releaseid=399059"}],"container-title":["Advances in Biochemical Engineering\/Biotechnology","Current Applications of Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/10_2019_105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T02:25:26Z","timestamp":1610763926000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/10_2019_105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030404635","9783030404642"],"references-count":162,"URL":"https:\/\/doi.org\/10.1007\/10_2019_105","relation":{},"ISSN":["0724-6145","1616-8542"],"issn-type":[{"value":"0724-6145","type":"print"},{"value":"1616-8542","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"6 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}